The association between haplotype variations in SLCO1B3 and SLCO1B1 and the differential response to MTX treatment observed in this study provides valuable insights into the genetic factors influencing drug efficacy in patients with RA. This evidence concerns the gene SLCO1B3 and rheumatoid arthritis.